Cargando…

1109. Valgancyclovir Dosing for Cytomegalovirus Prophylaxis in Heart Transplant Recipients

BACKGROUND: Cytomegalovirus (CMV) is one of the most common infections after transplantation and continues to cause significant morbidity and mortality. Current guidelines recommend 3-6 months of post-transplant prophylaxis with 900mg daily of valganciclovir in heart transplant recipients. At our in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Glen, Davis, Matthew R, Beaird, Omer E, Carlson, Margrit, Gaynor, Pryce, Multani, Ashrit, Deng, Mario, Nsair, Ali, Schaenman, Joanna M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776552/ http://dx.doi.org/10.1093/ofid/ofaa439.1295

Ejemplares similares

Spectrum of Coronavirus Disease 2019 Outcomes in Kidney Transplant Recipients: A Single-Center Experience
por: Lum, Erik, et al.
Publicado: (2020)

Transient SARS-CoV-2 RNA-Dependent RNA Polymerase Mutations after Remdesivir Treatment for Chronic COVID-19 in Two Transplant Recipients: Case Report and Intra-Host Viral Genomic Investigation
por: Yang, Shangxin, et al.
Publicado: (2023)

629. Blood Transcriptome Variations Predict Infection and Rejection in the Older Kidney Transplant Recipient
por: Schaenman, Joanna, et al.
Publicado: (2018)

Risk factors for infection in patients with a failed kidney allograft on immunosuppressive medications
por: Ogawa, Lauren, et al.
Publicado: (2023)

A Collaborative Tale of Diagnosing and Treating Chronic Pulmonary Aspergillosis, from the Perspectives of Clinical Microbiologists, Surgical Pathologists, and Infectious Disease Clinicians
por: Larkin, Paige M. K., et al.
Publicado: (2020)

Domestically Acquired NDM-1–Producing Pseudomonas aeruginosa, Southern California, USA, 2023
por: Gray, Hannah K., et al.
Publicado: (2023)

1702. Assessing the Safety and Efficacy of Valganciclovir Dosing for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients on Hemodialysis
por: Yee, Jason, et al.
Publicado: (2020)

Vaccine-Associated Measles in a Hematopoietic Cell Transplant Recipient: Case Report and Comprehensive Review of the Literature
por: Chang, Sandy Y, et al.
Publicado: (2021)

KIAA1109 Variants Are Associated with a Severe Disorder of Brain Development and Arthrogryposis
por: Gueneau, Lucie, et al.
Publicado: (2018)

Adenovirus in a Kidney Transplant Recipient
por: Lum, Erik L., et al.
Publicado: (2023)

Endosomal trafficking defects in patient cells with KIAA1109 biallelic variants
por: Kane, Megan S., et al.
Publicado: (2019)

1747. Impact of Inappropriately Low Cytomegalovirus (CMV) Prophylaxis Dosing on CMV Outcomes Among Lung Transplant (LT) Recipients
por: Watts, Corey, et al.
Publicado: (2019)

Effectiveness of valacyclovir prophylaxis against the occurrence of cytomegalovirus infection in kidney transplant recipients
por: Park, Woo Yeong, et al.
Publicado: (2020)

1573. Discrepancies Between Premortem and Postmortem Diagnoses of Infectious Diseases Found on Autopsy in Hematopoietic Cell Transplantation Recipients at a High-Volume Academic Transplant Center
por: Multani, Ashrit, et al.
Publicado: (2018)

1109 Knowledge and Attitudes of Pregnant Women Towards Recommendations for Immunization During Pregnancy
por: Healy, C. Mary, et al.
Publicado: (2014)

Letermovir for cytomegalovirus prophylaxis
Publicado: (2019)

Molecular Detection and Genotyping of Human Cytomegalovirus in Kidney Transplant Recipients under Ganciclovir Prophylaxis in Iran
por: Behnezhad, Farzane, et al.
Publicado: (2022)

Cost-effectiveness analysis of the use of letermovir for the prophylaxis of cytomegalovirus in adult cytomegalovirus seropositive recipients undergoing allogenic hematopoietic stem cell transplantation in Italy
por: Restelli, Umberto, et al.
Publicado: (2019)

KIAA1109 gene mutation in surviving patients with Alkuraya-Kučinskas syndrome: a review of literature
por: Kumar, Kishore, et al.
Publicado: (2020)

1109P The psychological impact of COVID-19 pandemic on patients with NETs: Between resilience and vulnerability
por: Lauricella, E., et al.
Publicado: (2021)

1109. Pharmacokinetics and Exposure of Cefepime in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
por: Kois, Abigail K, et al.
Publicado: (2021)

Cytomegalovirus infections in the blood recipient.
por: Nankervis, G. A.
Publicado: (1976)

Cytomegalovirus infection in transplant recipients
por: Azevedo*, Luiz Sergio, et al.
Publicado: (2015)

Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient
por: Jung, Susanne, et al.
Publicado: (2019)

Cytomegalovirus viraemia and mortality in renal transplant recipients in the era of antiviral prophylaxis. Lessons from the western Australian experience
por: Selvey, Linda A., et al.
Publicado: (2017)

A Mortality Analysis of Letermovir Prophylaxis for Cytomegalovirus (CMV) in CMV-seropositive Recipients of Allogeneic Hematopoietic Cell Transplantation
por: Ljungman, Per, et al.
Publicado: (2020)

Detection of Ganciclovir-Resistant Cytomegalovirus in a Prospective Cohort of Kidney Transplant Recipients Receiving Subtherapeutic Valganciclovir Prophylaxis
por: Wong, Diana D., et al.
Publicado: (2022)

928. Concordance with Institutional Guidelines for Letermovir Cytomegalovirus Infection Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Peterson-Weber, Alex, et al.
Publicado: (2023)

638. CMV-Specific T-Cell Immune Responses in Older vs. Younger Kidney Transplant Recipients
por: Liang, Emily, et al.
Publicado: (2018)

The Trend of Respiratory Virus Infection in Allogeneic Bone Marrow Transplant Recipients during the COVID Pandemic
por: Kaleka, Guneet, et al.
Publicado: (2022)

Risk Factors for Failure of Primary (Val)ganciclovir Prophylaxis Against Cytomegalovirus Infection and Disease in Solid Organ Transplant Recipients
por: Khurana, Mark P, et al.
Publicado: (2019)

Safety of Valganciclovir 450 mg 3 Times Weekly for Cytomegalovirus Prophylaxis in Solid Organ Transplant Recipients Requiring Hemodialysis
por: Ecabert, Danielle, et al.
Publicado: (2021)

Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high‐risk hematopoietic cell transplant recipients
por: Royston, Léna, et al.
Publicado: (2021)

Letermovir Prophylaxis and Cytomegalovirus Reactivation in Adult Hematopoietic Cell Transplant Recipients with and without Acute Graft Versus Host Disease
por: Wolfe, Delaney, et al.
Publicado: (2021)

1995. Duration of letermovir primary prophylaxis in hematopoietic cell transplant recipients at high risk for cytomegalovirus infections and impact on outcomes
por: Febres-Aldana, Anthony J, et al.
Publicado: (2023)

Correction to: Aspinall S, et al. Human Vaccines and Immunotherapeutics Volume 8, Issue 8; pp.1109–18
por: Aspinall, Sanet, et al.
Publicado: (2013)

Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients
por: Nicolosi, Maura, et al.
Publicado: (2018)

SG-APSIC1109: Redesign of outpatient clinic clean care to decrease postoperative SSIs after orthopedic implants
por: Dahesihdewi, Andaru, et al.
Publicado: (2023)

P1109: EPIDEMIOLOGY OF CUTANEOUS T-CELL LYMPHOMAS: DATA ANALYSIS FROM THE MARCHE MULTIDISCIPLINARY TEAM (MDT) REGISTER.
por: Morsia, Erika, et al.
Publicado: (2023)

Two dose-estimation models CSA-N288.1 and Nureg 1.109, 1.113 - compared for chronic aquatic releases from nuclear facilities
por: Sheppard, S C, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_1s8075v4kmso93o5p96k4od6i6